BS_T4P3J13C
Posterior Fossa Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Posterior Fossa Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Posterior Fossa Ependymoma
- overall_survival_months
- 51.51116951379763
- age_years
- 0.915
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.268
- CHOLESTEROL_HOMEOSTASIS+0.237
- BILE_ACID_METABOLISM+0.220
- WNT_BETA_CATENIN_SIGNALING+0.196
- ESTROGEN_RESPONSE_LATE+0.150
- KRAS_SIGNALING_DN+0.141
- XENOBIOTIC_METABOLISM+0.136
- FATTY_ACID_METABOLISM+0.118
- SPERMATOGENESIS+0.112
- PANCREAS_BETA_CELLS+0.111
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.459
- INTERFERON_GAMMA_RESPONSE-0.449
- PROTEIN_SECRETION-0.443
- MYC_TARGETS_V2-0.405
- UNFOLDED_PROTEIN_RESPONSE-0.373
- TNFA_SIGNALING_VIA_NFKB-0.357
- ALLOGRAFT_REJECTION-0.343
- MYC_TARGETS_V1-0.341
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.309
- IL2_STAT5_SIGNALING-0.298
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T4P3J13C | EPN | Posterior Fossa EPN | 0.881 |
| 2 | BS_C80S5N37 | Ependymoma NOS | — | 0.862 |
| 3 | TCGA-FJ-A3Z9-01A-11R-A26T-07 | — | — | 0.845 |
| 4 | SRR1337909 | GTEX | — | 0.843 |
| 5 | SJEPD001526_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.842 |
| 6 | TCGA-DK-A3IL-01A-11R-A20F-07 | — | — | 0.840 |
| 7 | BS_9RT63JD9 | low-grade glioma | — | 0.839 |
| 8 | MNG221 | — | — | 0.834 |
| 9 | SJEPD002_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.829 |
| 10 | MNG4 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.268 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.237 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.196 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.141 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.136 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.118 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.112 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.111 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.099 | Inavolisib | — uncovered |
| MYOGENESIS | 0.061 | Inavolisib | — uncovered |
| COAGULATION | 0.037 | Binimetinib | — uncovered |
| PEROXISOME | 0.034 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |